Kavigale (Sipavibart)

Sipavibart acts by binding to a specific molecular target that plays a role in pathogen replication or cellular signaling. This binding interferes with a critical step in the disease pathway, thereby reducing disease activity. The exact target and downstream effects are defined by the drug’s pharmacodynamic profile.

The dosage of Kavigale is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other relevant factors. No fixed dosing regimen is provided publicly; the prescriber tailors the dose to each individual case.

Safety data for Sipavibart in pregnancy and lactation are limited. It should only be used if the potential benefits justify the possible risks to the fetus or infant, and this decision must be made by the treating physician.

To request Kavigale, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Sipavibart belongs to a distinct pharmacological class with a unique mechanism of action. Compared with other agents targeting similar pathways, it may offer different efficacy or safety profiles, but direct comparative data are limited to clinical studies and should be reviewed by the prescribing clinician.

Kavigale must be stored at 2‑8 °C in a refrigerator, protected from light, and should not be frozen or shaken. Maintain the cold‑chain during transport and keep the product in its original packaging until use.

Kavigale is supplied as a sterile solution for injection and can be given either intramuscularly or intravenously by a qualified healthcare professional. The route, rate and site of administration are determined by the prescriber based on the therapeutic indication.

Serious risks include hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations, thrombocytopenia, neutropenia and renal impairment. Patients should be monitored closely for these events, and treatment should be discontinued if severe adverse reactions occur.

Kavigale should not be used in individuals with a known hypersensitivity to Sipavibart or any of the formulation components. Caution is also advised for patients with severe hepatic, renal or immunologic disorders, and the drug should be avoided in such cases unless a specialist determines that benefits outweigh risks.